UPDATE: S&P 500 erases 2016 gain as stocks retreat on disappointing jobs report
MARKET SNAPSHOT: Stocks End Higher After Jobs Report, But Book 2nd Weekly Decline In A Row
UPDATE: Stocks end higher after jobs report, but book 2nd weekly decline in a row
Why you shouldn't let oil crush your stock hopes
UPDATE: Why you shouldn't let oil crush your stock hopes
Biotech companies' returns have diverged from the broader market in recent weeks amid concerns over greater regulation and price discounting.
As the sector has continued to best the broader market, a look both at the dynamics that would drive further outperformance by the sector and at funds that investors can use to tap those themes.
This article represents opinions of the author and not those of his firm and are subject to change from time to time and do not constitute a recommendation to purchase and sale any security nor to engage in any particular investment strategy. The information contained here has been obtained from ...
The five biotech ETFs have very different portfolios with markedly different performance.
Jerry Slusiewicz depends on his own analysis and risk-management philosophy to keep client portfolios in order.